CD22 and colorectal carcinoma: CD22 (SIGLEC2), PD-1, BTLA, LAIR1, FCRL4 and CD327 (SIGLEC6) have been identified as inhibitors of BCR signaling (9, 25, 26), and therefore their expression was analyzed to assess the functional state of B cells in CRC samples of the PanCancer collection.